The PD1: PD-L1/2 pathway from discovery to clinical implementation
The immune system has the difficult challenge of discerning and defending against a diversity of microbial pathogens, while simultaneously avoiding self-reactivity. T lymphocytes function as effectors and regulators of the immune system. While central tolerance mechanism results in deletion of the m...
Main Authors: | Kankana Bardhan, Theodora Anagnostou, Vassiliki A Boussiotis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00550/full |
Similar Items
-
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01) -
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
by: Enrico Munari, et al.
Published: (2021-05-01) -
mRNA EXPRESSION OF PD-1, PD-L1, AND IMMUNOTHERAPY IN BLADDER CANCER
by: Muhammad Puteh Mauny, et al.
Published: (2021-07-01) -
Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
by: Robainas M, et al.
Published: (2017-03-01) -
Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)